RT Journal Article
T1 Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation
A1 Fernández Vázquez, María Inmaculada
A1 Meneu Díaz, Juan Carlos
A1 Colina Ruiz-Delgado, Francisco
A1 García, Ignacio
A1 Muñoz Gómez, Raquel
A1 Castellano Tortajada, Gregorio
A1 Fuertes, Antonio
A1 Abradelo De Usera, Manuel
A1 Lumbreras Bermejo, Carlos Juan
A1 Moreno González, Enrique
A1 Solís Herruzo, José Antonio
AB Treatment of recurrent hepatitis C in liver transplant is controversial. The aim of our study was to evaluate the clinical and histological efficacy of pegylated interferon alpha 2b (PEG-IFN) and ribavirin therapy of recurrent hepatitis C after liver transplantation (LT). We prospectively included 47 liver transplant patients with: 1) a positive test for hepatitis C virus (HCV)-ribonucleic acid (RNA) in serum; 2) alanine aminotransferase (ALT) >45 UI/mL; and 3) a liver biopsy showing chronic hepatitis without rejection in the previous 2 months. Patients received PEG-IFN (1.5 μg/kg/week) and ribavirin (800-1,000 mg/day) for 12 months. Follow-up was based on biochemical (ALT), virological (RNA-HCV), and histological (liver biopsy) examinations. Follow-up lasted a minimum of 6 months after the end of antiviral therapy. Sustained virological response (SVR) was achieved in 23% of the patients. A total of 33 (70%) patients had normalized ALT levels at the end of therapy. Inflammatory portal and lobular score declined significantly in patients with SVR (P < 0.05) but not in nonresponder patients. Fibrosis did not change significantly in either group. SVR was significantly associated with low γ-glutamyltransferase GGT (P = 0.04) and HCV-RNA levels (P = 0.03), a virological response at 12 weeks (P = 0.002) and patient's compliance (P = 0.04). Ten (21%) patients were withdrawn prematurely due to adverse effects. In conclusion, Therapy with PEG-IFN and ribavirin achieved SVR and a significant histological improvement in 23% of liver transplant recipients with chronic hepatitis C. Toxicity is an important drawback of this therapy. Liver Transpl 12:1805-1812, 2006. © 2006 AASLD.
PB Wiley
SN 1527-6465
YR 2006
FD 2006
LK https://hdl.handle.net/20.500.14352/114121
UL https://hdl.handle.net/20.500.14352/114121
LA eng
NO Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, Fuertes A, Abradelo M, Lumbreras C, Moreno E, Solís-Herruzo JA. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl. 2006 Dec;12(12):1805-12. doi: 10.1002/lt.20883.
DS Docta Complutense
RD 25 dic 2025